BridgeMD
Study of MRM-3379 in Male Participants with Fragile X Syndrome
EU CTIS ID: 2025-523738-21-00
What this study is testing
To evaluate the safety and tolerability of MRM-3379 in male participants with FXS on the basis of the following endpoints: - Incidence and severity of TEAEs - Withdrawal due to AEs
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Willing and able to provide signed informed consent/assent. Where local regulations permit inclusion of participants deemed unable to provide informed consent, a legally authorized representative must provide informed consent on the participant’s behalf, and the participant must provide assent if applicable.
- Male, 13–45 years of age (inclusive).
- Weight ≥30 kg and BMI ≥18 and <36 kg/m2 (inclusive)
- Diagnosis of FXS with a molecular genetic ≥200 CGG repetitions.
- Have a consistent caregiver(s) who is willing and able to be present regularly and reliably with the participant.
- Able to swallow tablets or capsules
You likely can't join if
- History of or current medical condition other than FXS and related issues that would place the participant at higher risk from study participation.
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18-64 years, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.